The aim of this study was to investigate the relationship between circulating monocytes and in-stent neointimal volume at six-month follow-up. BACKGROUND In-stent neointimal hyperplasia is the main contributing factor to in-stent restenosis. There is increasing evidence that white blood cells (WBCs), especially monocytes, play a central role in restenosis after stent implantation.
Stent implantation for coronary artery disease is now established as a therapeutic strategy of great benefit (1, 2) . However, in-stent restenosis, which is a main limitation of coronary stent implantation, remains unresolved (3) .
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Excessive in-stent neointimal hyperplasia is the main contributing factor to in-stent restenosis (4, 5) . There is increasing evidence from several experimental studies that white blood cells (WBCs), especially monocytes, play a central role in restenosis after balloon angioplasty and stent implantation (6 -9) . Previous studies have demonstrated infiltration and accumulation of monocytes to the stenting site, and these cells correlate with smooth muscle cell (SMC) proliferation and neointimal growth (6, 7) . Also, monocytes/macrophages have been demonstrated to be one of the components of the neointima (9) . However, there are few studies that investigate the relationship between circulating monocytes and in-stent neointima of human stented lesions.
The aim of this study was to investigate the relationship between circulating monocytes and in-stent neointimal volume at six-month follow-up. We monitored the serial changes in the monocyte count after stent implantation and evaluated the relationship with in-stent neointimal volume.
METHODS
Patient enrollment. Our patient population comprised 107 consecutive patients (107 lesions) who received successful intravascular ultrasound (IVUS)-guided single-stent (stent length 15 mm) implantation between May 2001 and March 2002 and returned for scheduled six-month followup analysis. In this study, patients who met the following criteria were excluded: 1) patients with a restenotic lesion from a previous intervention; 2) patients requiring multiple stenting in one lesion; 3) patients having a culprit lesion with an arc of calcification Ն90°; and 4) patients with a left main coronary artery lesion or chronic total occlusion lesion.
To examine the effect of coronary angiography itself on each WBC fraction count, we selected 131 patients who underwent coronary angiography but had no intervention in the same period as a non-intervention group.
Protocol for intervention and follow-up. Coronary angiography was performed using a standard technique (10) . All patients initially received a bolus injection of 10,000 IU heparin and intracoronary isosorbide dinitrate (5 mg) before angiography. After completion of the diagnostic coronary angiogram, pre-intervention IVUS was performed using a 0.014-inch (0.035-cm) guide wire. The IVUS catheter (3.2F; Ultra Cross, Boston Scientific Scimed, Inc., Maple Grove, Minnesota) was carefully advanced distal to the lesion under fluoroscopic guidance. It was then pulled back automatically from the distal portion at 0.5 mm/s to the culprit lesion, and the vessel diameter (media to media) was measured. All IVUS images were recorded on S-VHS videotape for off-line analysis. After IVUS evaluation, balloon pre-dilation and primary stenting were performed using a Multi-Link stent (ACS, Santa Clara, California) sized to 90% of the media-to-media diameter on IVUS and dilated at 14 atm. After stent implantation, a non-compliant balloon, sized in the same way, was used for post-dilation at Ն10 atm, with the inflation pressure increased until the minimum lumen area of the stented site was Ն80% of the distal reference cross-sectional area (CSA) on IVUS. All patients were started on a post-procedural regimen of 81 mg/day aspirin and 200 mg/day ticlopidine hydrochloride.
At scheduled six-month follow-up, patients received a bolus injection of 3,000 IU heparin and 5 mg intracoronary isosorbide dinitrate, with coronary angiography and volumetric IVUS analysis using the same protocol. The protocol for the study was approved by the Ethics Committee of Osaka City University Hospital. We obtained written, informed consent from all participants before coronary angiography and stent implantation. Measurement of WBC count. Peripheral blood was obtained from all patients immediately before coronary angiography and every day for seven days after the procedure. Blood sampling was performed carefully and gently to avoid 
RESULTS

Patient characteristics.
Baseline patient characteristics are shown in Table 1 . In our study population, there was no in-hospital death or subacute stent thrombosis, and during the follow-up period, there were also no major adverse cardiac events. Follow-up angiography and IVUS evaluation were performed at 6.5 Ϯ 1.1 months in all patients (107 lesions). At follow-up, angiographic in-stent restenosis was observed in 22 patients (21%). Peripheral monocyte count. The serial changes in each WBC fraction count are shown in Figure 1 . The monocyte count increased after stent implantation and reached its peak two days after the procedure (from 350 Ϯ 167 to 515 Ϯ 149/mm 3 , p Ͻ 0.01). However, other fractions had no significant change. Also, patients with restenosis showed a significantly larger maximum monocyte count than did patients without restenosis (642 Ϯ 110 vs. 529 Ϯ 77/mm 3 , p Ͻ 0.001), as shown in Figure 2 . Patients in the nonintervention group showed no significant serial changes in each WBC fraction count, including monocytes, as shown in Figure 3 . Relationship between monocyte count and in-stent neointimal volume. The maximum monocyte count after stent implantation showed a significant positive correlation with in-stent neointimal volume at six-month follow-up (r ϭ 0.44, p Ͻ 0.0001), as shown in Figure 4 . However, other fractions had no correlation with in-stent neointimal volume. Multiple regression analysis revealed that in-stent neointimal volume was independently correlated with stent volume immediately after stent implantation (r ϭ 0.45, p Ͻ 0.0001) and maximum monocyte count (r ϭ 0.35, p Ͻ 0.001), as shown in Table 2 . Figure 5 shows typical cases of patients with restenosis (part A) and without restenosis (part B). Both of these patients underwent stent implantation in the mid right coronary artery portion using a 3.5-mm Multi-Link stent (stent length 15 mm). One patient (Fig. 5A) presented with 76.12 mm 3 of in-stent neointima and 621/mm 3 maximum monocyte count, whereas another patient (Fig. 5B) had 27.9 mm 3 of in-stent neointima and 259/mm 3 maximum monocyte count. Fukuda et al. January 7, 2004:18-23 Monocytes and In-Stent Neointima
DISCUSSION
Previously, the important role of WBCs, especially monocytes, in in-stent neointimal proliferation has been demonstrated, although no study has revealed the relationship between in-stent neointima and circulating monocytes. We showed the positive correlation between circulating monocytes and in-stent neointimal volume in human stented lesions. The SMCs are known to be the major cellular component of in-stent neointima. Excessive accumulation of SMCs has a key role in in-stent neointimal hyperplasia; however, the origin of SMCs is still not well established. Neointimal SMCs were thought to originate locally from the SMCs of the medial layer in the vascular injury models and graft vasculopathy models (11, 12) . Adherent activated monocytes/macrophages secrete numerous growth factors, cytokines, and metalloproteinases and promote the migration and proliferation of SMCs to the subendothelial space (13) (14) (15) . Our results may reflect the monocyte-related migration and proliferation of SMCs and neointimal growth.
The advance of stem-cell science has revealed that bone marrow contains multipotent adult stem cells with a high capacity for differentiation (16 -20) . The peripheral monocyte fraction, as we focused on in this study, is known to include bone marrow stem cells (21, 22) . Previous reports have demonstrated that neointimal lesions in graft vasculopathy models were formed by the attachment and proliferation of recipient circulating SMC progenitor cells, and these reports have also demonstrated that bone marrow cells contribute to neointimal lesions in vascular injury models (23, 24) . Also, other reports have demonstrated that circulating endothelial progenitor cells derived from bone marrow incorporate into re-endothelialization after vascular injury (25, 26) . A more recent study has reported the outgrowth of SMCs from peripheral circulating mononuclear cells (27) . Our results suggest a possible mechanism by which increased monocytes, including progenitor cells, derived from bone marrow, differentiate to the neointimal SMCs and contribute to neointimal formation in human stented lesions.
The origin of SMCs is still controversial, and further Figure 5 . Typical examples of patients with restenosis (A) and without restenosis (B). Both of these patients underwent stent implantation in the mid right coronary artery portion using a 3.5-mm Multi-Link stent (15 mm in length) (arrows). The patient with restenosis presented with 76.12 mm 3 of in-stent neointima and 621/mm 3 maximum monocyte count, whereas the patient without restenosis had 27.9 mm 3 of in-stent neointima and 259/mm 3 maximum monocyte count. studies are needed. In either case, circulating monocytes may play an important role in the process of neointimal proliferation after stent implantation in humans. Study limitations. Our study has several limitations. We did not investigate membrane antigen of monocytes, so the exact origin of increasing monocytes after stent implantation was unclear. In addition, functional analysis of monocytes was not performed. Finally, to analyze each WBC fraction count, we only performed automated measurements in this study. Clinical implication. Our results suggest that circulating monocytes relate to the process of in-stent neointimal hyperplasia in human stented lesions. This proposes a new point of view of mechanisms of in-stent restenosis and suggests a new therapeutic target.
